BACKGROUND: Sub-Saharan Africa bears an inordinate burden of human immunodeficiency virus (HIV) infection/acquired immune deficiency syndrome (AIDS). Reports have shown increased prevalence of clustering of cardiovascular risk factors referred to as metabolic syndrome in treatment-naïve patients and patients on highly active antiretroviral therapy (HAART). In view of the fact that metabolic syndrome is a heterogeneous disorder with substantial variability in the prevalence and component traits within and across populations and the dearth of publications on the prevalence and clinical correlates of metabolic syndrome in people living with HIV/AIDS (PLWHA) in Nigeria, this study was carried out to determine the prevalence and clinical correlates of metabolic syndrome among an HIV-infected outpatient population using the National Cholesterol Education Adult Treatment Panel III (NCEP ATP III), the International Diabetes Federation (IDF), and the Joint Interim Statement (JIS) definitions. We also sought to determine if HAART use and CD4 count level were associated with metabolic syndrome. METHODS: This cross-sectional study involved 291 (95 men, 196 women) consecutive PLWHA. Anthropometry, blood pressure, fasting plasma glucose, and lipid profile values were determined. RESULTS: The prevalence rates of metabolic syndrome according to the ATP III, IDF, and JIS criteria were 12.7%, 17.2%, and 21.0%, respectively. Metabolic syndrome was significantly associated with female gender (all definitions), body mass index (all definitions), increasing age, and CD4 count (IDF definition). There was no significant association between metabolic syndrome and HAART. The concordance [kappa coefficient (κ)] between the definitions of metabolic syndrome varied between 0.583 and 0.878. CONCLUSIONS: The prevalence of metabolic syndrome varied with the criteria used and metabolic syndrome correlates with traditional cardiovascular risk factors rather than HAART-related factors.
BACKGROUND: Sub-Saharan Africa bears an inordinate burden of human immunodeficiency virus (HIV) infection/acquired immune deficiency syndrome (AIDS). Reports have shown increased prevalence of clustering of cardiovascular risk factors referred to as metabolic syndrome in treatment-naïve patients and patients on highly active antiretroviral therapy (HAART). In view of the fact that metabolic syndrome is a heterogeneous disorder with substantial variability in the prevalence and component traits within and across populations and the dearth of publications on the prevalence and clinical correlates of metabolic syndrome in people living with HIV/AIDS (PLWHA) in Nigeria, this study was carried out to determine the prevalence and clinical correlates of metabolic syndrome among an HIV-infectedoutpatient population using the National Cholesterol Education Adult Treatment Panel III (NCEP ATP III), the International Diabetes Federation (IDF), and the Joint Interim Statement (JIS) definitions. We also sought to determine if HAART use and CD4 count level were associated with metabolic syndrome. METHODS: This cross-sectional study involved 291 (95 men, 196 women) consecutive PLWHA. Anthropometry, blood pressure, fasting plasma glucose, and lipid profile values were determined. RESULTS: The prevalence rates of metabolic syndrome according to the ATP III, IDF, and JIS criteria were 12.7%, 17.2%, and 21.0%, respectively. Metabolic syndrome was significantly associated with female gender (all definitions), body mass index (all definitions), increasing age, and CD4 count (IDF definition). There was no significant association between metabolic syndrome and HAART. The concordance [kappa coefficient (κ)] between the definitions of metabolic syndrome varied between 0.583 and 0.878. CONCLUSIONS: The prevalence of metabolic syndrome varied with the criteria used and metabolic syndrome correlates with traditional cardiovascular risk factors rather than HAART-related factors.
Authors: Alfred Osoti; Tecla M Temu; Nicholas Kirui; Edmond K Ngetich; Jemima H Kamano; Stephanie Page; Carey Farquhar; Gerald S Bloomfield Journal: AIDS Patient Care STDS Date: 2018-06 Impact factor: 5.078
Authors: Ditte Steiniche; Sanne Jespersen; Christian Erikstrup; Henrik Krarup; Aase Handberg; Lars Østergaard; Thorny Haraldsdottir; Candida Medina; Faustino Gomes Correira; Alex Lund Laursen; Morten Bjerregaard-Andersen; Christian Wejse; Bo Langhoff Hønge Journal: Trans R Soc Trop Med Hyg Date: 2016-04 Impact factor: 2.184
Authors: Felistas Mashinya; Marianne Alberts; Jean-Pierre Van Geertruyden; Robert Colebunders Journal: AIDS Res Ther Date: 2015-12-10 Impact factor: 2.250
Authors: Nazik Elmalaika Husain; Sufian K Noor; Wadie M Elmadhoun; Ahmed O Almobarak; Heitham Awadalla; Clare L Woodward; Dushyant Mital; Mohamed H Ahmed Journal: HIV AIDS (Auckl) Date: 2017-11-08
Authors: Kim Anh Nguyen; Nasheeta Peer; Anniza de Villiers; Barbara Mukasa; Tandi E Matsha; Edward J Mills; Andre Pascal Kengne Journal: Int J Endocrinol Date: 2017-03-14 Impact factor: 3.257
Authors: Adeolu Oladayo Akinboro; Olaniyi Onayemi; Olugbenga Edward Ayodele; Ayodele David Mejiuni; Adeniran Samuel Atiba Journal: Pan Afr Med J Date: 2013-07-12